AIM-listed biopharmaceutical company GW Pharmaceuticals has reported that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for US application serial number 13/606,742, a patent application directed to the spray device of its Sativex product formulation. [22 Apr '13]
AIM-listed specialty pharmaceutical company GW Pharmaceuticals expects to account for a provision of 0.8m pounds in the financial year ending September 30th 2013 reflecting the impact of a pricing decision on its multiple sclerosis treatment Sativex. [19 Mar '13]
Clean energy products company Acta has announced the shipment of the first fully integrated fuel cell telecom back-up power system, incorporating Acta's onboard hydrogen generation for automatic fuel replenishment. The completed system has been shipped to Acta's Australian marketing and distribution partner and is to be put on field trial with a major Australian telecoms company in the near future. The company said that on the basis of a five-year total cost of ownership, the [1 Oct '12]
Elementis traces its roots to 1844 and the Harrisons & Crosfield tea and coffee trading conglomerate, but it took its present shape in 1998, when the company focused on chemicals found in substances such as paint, cosmetics and, more recently, shale gas wells, where the flow of a substance needs to be controlled. Elementis, which trades on 15 times Brewin Dolphin forecasts, has shed its volatile past and consistently overdelivered on the earnings front. It looks to be in its element and could flow higher, says the Times. [5 Jul '11]
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.